These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30629858)

  • 41. Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.
    Kawakami Y; Imamura M; Ikeda H; Suzuki M; Arataki K; Moriishi M; Mori N; Kokoroishi K; Katamura Y; Ezaki T; Ueno T; Ide K; Masaki T; Ohdan H; Chayama K
    J Viral Hepat; 2016 Nov; 23(11):850-856. PubMed ID: 27346670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
    Miyazaki R; Miyagi K
    Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
    Harada N; Yoshizumi T; Ikegami T; Itoh S; Furusho N; Kato M; Shimoda S; Fukuhara T; Soejima Y; Maehara Y
    Anticancer Res; 2018 Sep; 38(9):5513-5520. PubMed ID: 30194210
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.
    Maekawa S; Sato M; Kuratomi N; Inoue T; Suzuki Y; Tatsumi A; Miura M; Matsuda S; Muraoka M; Nakakuki N; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Sato T; Sakamoto M; Murakawa M; Nakagawa M; Asahina Y; Enomoto N
    J Gastroenterol; 2018 Jun; 53(6):780-786. PubMed ID: 29094205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
    Kai Y; Hikita H; Tatsumi T; Nakabori T; Saito Y; Morishita N; Tanaka S; Nawa T; Oze T; Sakamori R; Yakushijin T; Hiramatsu N; Suemizu H; Takehara T
    J Gastroenterol; 2015 Nov; 50(11):1145-51. PubMed ID: 26208695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.
    Akamatsu N; Sugawara Y; Kokudo N
    Expert Rev Anti Infect Ther; 2015; 13(11):1307-17. PubMed ID: 26414905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
    Ueno T; Osawa M; Imai Y; Ishikawa H; Garimella T
    J Clin Pharmacol; 2018 Nov; 58(11):1479-1488. PubMed ID: 30063245
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beclabuvir for the treatment of hepatitis C.
    Gentile I; Zappulo E; Buonomo AR; Maraolo AE; Borgia G
    Expert Opin Investig Drugs; 2015; 24(8):1111-21. PubMed ID: 26156630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
    Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
    J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
    Uchida Y; Naiki K; Kouyama JI; Sugawara K; Nakao M; Motoya D; Inao M; Nakayama N; Imai Y; Tomiya T; Mochida S
    PLoS One; 2018; 13(10):e0205600. PubMed ID: 30308053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful Treatment of Fibrosing Cholestatic Hepatitis With Daclatasvir and Asunaprevir After Liver Transplantation: A Case Report.
    Jung BH; Park JI; Lee SG
    Transplant Proc; 2018 Nov; 50(9):2877-2881. PubMed ID: 30401415
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
    Akuta N; Sezaki H; Suzuki F; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2016 Mar; 88(3):506-11. PubMed ID: 26292191
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.
    Kanda T; Yasui S; Nakamura M; Suzuki E; Arai M; Haga Y; Sasaki R; Wu S; Nakamoto S; Imazeki F; Yokosuka O
    Int J Med Sci; 2016; 13(6):418-23. PubMed ID: 27279790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection.
    Zhu L; Li H; Chan P; Eley T; Gandhi Y; Bifano M; Osawa M; Ueno T; Hughes E; AbuTarif M; Bertz R; Garimella T
    Infect Dis Ther; 2018 Jun; 7(2):261-275. PubMed ID: 29589331
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.
    Wada N; Ikeda F; Mori C; Takaguchi K; Fujioka SI; Kobashi H; Morimoto Y; Kariyama K; Sakaguchi K; Hashimoto N; Moriya A; Kawaguchi M; Miyatake H; Hagihara H; Kubota J; Takayama H; Takeuchi Y; Yasunaka T; Takaki A; Iwasaki Y; Okada H
    Acta Med Okayama; 2018 Aug; 72(4):401-406. PubMed ID: 30140089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
    Wei L; Zhang M; Xu M; Chuang WL; Lu W; Xie W; Jia Z; Gong G; Li Y; Bae SH; Yang YF; Xie Q; Lin S; Chen X; Niu J; Jia J; Garimella T; Torbeyns A; McPhee F; Treitel M; Yin PD; Mo L
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1860-1867. PubMed ID: 27003037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience.
    Ikegami T; Ueda Y; Akamatsu N; Ishiyama K; Goto R; Soyama A; Kuramitsu K; Honda M; Shinoda M; Yoshizumi T; Okajima H; Kitagawa Y; Inomata Y; Ku Y; Eguchi S; Taketomi A; Ohdan H; Kokudo N; Shimada M; Yanaga K; Furukawa H; Uemoto S; Maehara Y
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28881052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.
    Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2017 Nov; 32(11):1879-1886. PubMed ID: 28258705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Asunaprevir for hepatitis C: a safety evaluation.
    Gentile I; Zappulo E; Buonomo AR; Scotto R; Borgia G
    Expert Opin Drug Saf; 2015 Oct; 14(10):1631-46. PubMed ID: 26329454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.